High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
about
Recent developments in using mechanistic cardiac modelling for drug safety evaluationComputer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challengesThe effects of different wavelength UV photofunctionalization on micro-arc oxidized titaniumPrediction of Thorough QT study results using action potential simulations based on ion channel screensEvaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.Predicting QTc Prolongation in Man From Only In Vitro Data.Systems Toxicology: Real World Applications and Opportunities.Computational modeling of inhibition of voltage-gated Ca channels: identification of different effects on uterine and cardiac action potentials.A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment.Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century.Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation.A new paradigm for predicting risk of Torsades de Pointes during drug development: Commentary on: "Improved prediction of drug-induced Torsades de Pointes through simulations of dynamics and machine learning algorithms".A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.Multiscale Modeling in the Clinic: Drug Design and DevelopmentA temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.Computational Models for Predictive Cardiac Ion Channel Pharmacology.Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk AssessmentMitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation.Human induced pluripotent stem cell-derived versus adult cardiomyocytes: an in silico electrophysiological study on effects of ionic current block.hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.Technological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance.Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study.In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil Is in the Details.Sinusoidal voltage protocols for rapid characterisation of ion channel kinetics.Determinants of Isoform-Specific Gating Kinetics of hERG1 Channel: Combined Experimental and Simulation Study.Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future ChallengesSurface Modification of Porous Titanium with Microarc Oxidation and Its Effects on Osteogenesis ActivityIn Vitro
P2860
Q26764870-94C16BD8-9C55-4544-951F-76F935A3AB05Q26861453-06B3C4CB-4277-4994-B4AA-63AC9FF5FC08Q28534544-096D7C21-6BA1-42E8-8555-A37D99E42355Q28649794-25C59D6D-8A31-4FC9-9B39-B977792579B4Q30620268-A090D5D5-CD63-4082-9BB1-CFD6350E5C44Q30843780-6DE3B6DD-17AA-4919-BDC5-0DB714545D3FQ33577370-123D84FC-9DBF-461A-9BEC-25ADCFC13737Q34349461-FF476E1C-D521-4182-962B-8553B007984AQ35211741-CCB8AA8D-81E6-4BE5-9E19-D204884BDF73Q37466831-3785B137-C1E6-4575-8FBB-F98B4D1AAF73Q37579944-55C22CFA-BB14-4C6D-A252-AC368E0746C1Q37648854-D1C111E9-4070-4930-B591-E9741731254AQ38546437-3D3CCD20-BAB4-4663-9721-69C76EDEC7EEQ38736948-4EC02675-2609-466B-ADF1-1D685BBADFF6Q39767396-F23AEE68-2776-4748-9BAE-B48497B99E33Q40243231-1288315D-2674-42F3-A5EB-497FE514F2A8Q41524806-1491DAFB-9293-4D50-BD8D-964ECAF47455Q41846759-F227DB4C-27CB-41C7-AF90-3B16296C702CQ42606979-A03F875E-6270-4FA7-8956-EFA7974AF467Q45382195-363AFBE5-2A04-452F-AB76-3F2F1350593CQ45967235-C2511870-EB0B-4F67-B8C4-B9D7A418BBD9Q45981926-EB91441A-F19F-47BB-9438-086CA9E74860Q47095257-DA72E0B5-86B5-4656-B9DD-757EEB458CA7Q52638848-4EDA4925-D21B-4012-BBCD-AB1CCD886A8DQ53828026-42AD1C45-5053-4B11-9151-C1218CC543CBQ57161239-7EB7283A-93C1-47E7-A2B3-245BA9C666C0Q59113439-EFC2D36D-33D2-4F4D-A734-CA6DD616E3E7
P2860
High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
High-throughput screening of d ...... early drug safety assessment.
@en
High-throughput screening of d ...... early drug safety assessment.
@nl
type
label
High-throughput screening of d ...... early drug safety assessment.
@en
High-throughput screening of d ...... early drug safety assessment.
@nl
prefLabel
High-throughput screening of d ...... early drug safety assessment.
@en
High-throughput screening of d ...... early drug safety assessment.
@nl
P2093
P2860
P1476
High-throughput screening of d ...... early drug safety assessment.
@en
P2093
Giovanni Y Di Veroli
Henggui Zhang
Najah Abi-Gerges
P2860
P304
P356
10.1152/AJPHEART.00511.2012
P577
2012-10-26T00:00:00Z